Monoclonal antibody treatment of solid tumors: a coming of age.

abstract：:While cancers of the upper gastrointestinal tract are related by location, they have distinct clinical and molecular characteristics. This review will focus on the molecular biology of esophageal adenocarcinoma (EAC) of which alterations in p53, overexpression of cyclin D1, loss of p16, and aneuploidy have been best c...

journal_title：Seminars in oncology

authors： Lin J,Beerm DG

更新日期：2004-08-01 00:00:00

abstract：:Metastatic cancers during pregnancy have historically been associated with dismal outcomes, with greater rates of tumor progression in part because of diminished treatment alternatives. Immunotherapy with T-cell checkpoint inhibitors has significantly impacted the survival of several metastatic tumors. However, given ...

journal_title：Seminars in oncology

authors： Burotto M,Gormaz JG,Samtani S,Valls N,Silva R,Rojas C,Portiño S,de la Jara C

更新日期：2018-06-01 00:00:00

abstract：:In recent years, the most frequent indication for high-dose autologous stem-cell-supported chemotherapy in the United States has been breast cancer. This approach is applied in "high-risk," early-stage disease as adjuvant treatment, and with either curative or palliative intent in metastatic disease. Among both lay pe...

journal_title：Seminars in oncology

authors： Hudis CA,Münster PN

更新日期：1999-02-01 00:00:00

abstract：:We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. Patients who did not require therapy for more than 1 year (n = 54) could be distinguis...

journal_title：Seminars in oncology

authors： Dhodapkar MV,Jacobson JL,Gertz MA,Crowley JJ,Barlogie B

更新日期：2003-04-01 00:00:00

abstract：:The recommended weekly dose and the maximum tolerated weekly dose of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) have yet to be determined. We report that a weekly dose of up to 40 mg/m2 docetaxel for 6 weeks is active in pretreated patients with metastatic breast cancer. From a preliminary study, this d...

journal_title：Seminars in oncology

authors： Löffler TM

更新日期：1998-10-01 00:00:00

abstract：:The results of recent clinical trials have shown that docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France), like paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ), has high levels of activity in patients with anthracycline-resistant breast cancer. Agents that are at least partially non-cross-resist...

journal_title：Seminars in oncology

authors： Ravdin PM

更新日期：1995-12-01 00:00:00

abstract：:The humanized anti-p185(HER2) monoclonal antibody trastuzumab has been shown to effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The treatment of cancer cells with trastuzumab results in downregulation of the HER2 receptor. Further downstream cellular events include the a...

journal_title：Seminars in oncology

authors： Baselga J,Albanell J,Molina MA,Arribas J

更新日期：2001-10-01 00:00:00

abstract：:For any tumor to become cancerous, various genetic mutations and biologic alterations must occur in the cell that in combination render it a malignant neoplasm. Small cell lung cancer (SCLC) is a neoplasm associated with several molecular and cellular abnormalities. SCLC is associated with early and frequent metastasi...

journal_title：Seminars in oncology

authors： Sattler M,Salgia R

更新日期：2003-02-01 00:00:00

abstract：:Although bone and soft tissue sarcomas are not common, a significant number of patients who develop these tumors will die with metastatic disease. Part of the reason is that many of the patients have advanced disease at diagnosis. Identification of an etiologic agent should allow for diagnosis at an earlier stage. Thi...

journal_title：Seminars in oncology

authors： McClay EF

更新日期：1989-08-01 00:00:00

abstract：:Colorectal cancer (CRC) is a common malignancy in the elderly. Randomized trials have demonstrated that adjuvant and palliative chemotherapy for CRC improves survival and quality of life. Unfortunately, there is a lack of evidence-based data about elderly patients to guide decisions regarding therapy. Clinical trials ...

journal_title：Seminars in oncology

authors： Raftery L,Sanoff HK,Goldberg R

更新日期：2008-12-01 00:00:00

abstract：:The natural history of squamous cell head and neck cancer is well understood. Locoregional approaches to salvage therapy for this disease have curative potential, primarily because distant metastases are uncommon. Before proceeding with salvage treatment, however, clinicians should identify the extent of disease and d...

journal_title：Seminars in oncology

authors： Adelstein DJ

更新日期：1994-08-01 00:00:00

abstract：:Intra-arterial (IA) therapies for hepatocellular carcinoma (HCC) are considered palliative and should be offered to patients with intermediate-stage multinodular disease and with sufficient liver reserve. They include transarterial chemoembolization (TACE) or bland embolization, transarterial chemotherapy, and transar...

journal_title：Seminars in oncology

authors： Tsochatzis EA,Germani G,Burroughs AK

更新日期：2010-04-01 00:00:00

abstract：:Lymphoma and myeloma represent an increasingly important cause of morbidity and mortality in the older patient group. Studies to date, while limited, suggest that there may be differences in the underlying biology of the tumor cell of some lymphoid malignancies in younger versus older patients. Significant new data wi...

journal_title：Seminars in oncology

authors： Westin EH,Longo DL

更新日期：2004-04-01 00:00:00

abstract：:The epidemiologic literature suggests that environmental exposures, familial susceptibility, and cytogenetic changes affect AML risk in childhood and adulthood. Unfortunately, many studies are limited by inadequate sample sizes, imprecise case definition, or inadequate exposure measurement. Few studies have singled ou...

journal_title：Seminars in oncology

authors： Sandler DP

更新日期：1987-12-01 00:00:00

abstract：:Angiogenesis is required for multistage carcinogenesis. The inducible enzyme cyclooxygenase-2 (COX-2) is an important mediator of angiogenesis and tumor growth. COX-2 expression occurs in a wide range of preneoplastic and malignant conditions; and the enzyme has been localized to the neoplastic cells, endothelial cell...

journal_title：Seminars in oncology

authors： Gately S,Li WW

更新日期：2004-04-01 00:00:00

abstract：:It has been a challenge to find effective chemotherapeutic treatments for malignant mesothelioma. Over the last several decades numerous single-drug and combination regimens have been examined, but no standard treatment with chemotherapy alone has emerged. Possible explanations for this lack of success are the heterog...

journal_title：Seminars in oncology

authors： Baas P

更新日期：2002-02-01 00:00:00

abstract：:The limited single-agent activity of cisplatin, its toxicity profile, and the inconvenience involved in hydrating patients has compelled researchers to investigate other treatments as possible alternative therapies in non-small cell lung cancer. More recently, interest has focused on the potential of nonplatinum combi...

journal_title：Seminars in oncology

authors： Georgoulias V,Scagliotti G,Miller V,Eckardt J,Douillard JY,Manegold C

更新日期：2001-02-01 00:00:00

abstract：:Letrozole has proven efficacious in a variety of therapeutic scenarios, including that of extended adjuvant therapy following 5 years of tamoxifen treatment in postmenopausal women with estrogen-receptor-positive early breast cancer. The Breast International Group 1-98 trial (BIG 1-98) is the first to study the effica...

journal_title：Seminars in oncology

authors： Forbes JF

更新日期：2006-04-01 00:00:00

abstract：:Gemcitabine is a novel nucleoside analogue that has demonstrated activity against several solid tumors. A large phase II study has been performed in Europe and Canada with a total enrollment of 161 non-small cell lung cancer patients, 26 of whom were from the Institut Gustave-Roussy. Patient characteristics were the s...

journal_title：Seminars in oncology

authors： Le Chevalier T,Gottfried M

更新日期：1997-04-01 00:00:00

abstract：:Hormonal therapy is very effective in the treatment of patients with metastatic breast cancer. Response to various therapies leads to improved quality of life and prolonged survival. This clinical trial compared two commonly utilized additive hormonal agents, tamoxifen citrate and megestrol acetate (Megace). Prelimina...

journal_title：Seminars in oncology

authors： Allegra JC,Bertino J,Bonomi P,Byrne P,Carpenter J,Catalano R,Creech R,Dana B,Durivage H,Einhorn L

更新日期：1985-12-01 00:00:00

abstract：:Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

journal_title：Seminars in oncology

authors： Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

更新日期：1990-02-01 00:00:00

abstract：:Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passiv...

journal_title：Seminars in oncology

authors： Hwang LC,Fein S,Levitsky H,Nelson WG

更新日期：1999-04-01 00:00:00

abstract：:To address the urgent need for novel therapies for multiple myeloma (MM), long-term research efforts have characterized the mechanisms whereby MM cells home to the bone marrow and adhere to bone marrow stromal cells and extracellular matrix proteins. Research also characterizes the functional sequelae of this binding ...

journal_title：Seminars in oncology

authors： Anderson KC

更新日期：2002-12-01 00:00:00

abstract：:A large body of work spanning the past decade has identified the molecular chaperone heat shock protein 90 (Hsp90) as a critical modulator of an extensive network of cellular signaling pathways. Many of the processes overseen by Hsp90 are deregulated in tumor cells, including cell cycle control, gene transcription, an...

journal_title：Seminars in oncology

authors： Cullinan SB,Whitesell L

更新日期：2006-08-01 00:00:00

abstract：:The optimal management of early stage ovarian cancer with poor prognostic features remains controversial. On the basis of results of studies in advanced ovarian cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in combination with a platinum agent has become part of adjuvant chemotherapy trials i...

journal_title：Seminars in oncology

authors： Young RC

更新日期：2000-06-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent w...

journal_title：Seminars in oncology

authors： Manegold C

更新日期：1998-08-01 00:00:00

abstract：:Acute and chronic graft-versus-host disease (GvHD) remain major obstacles to successful allogeneic hematopoietic stem cell transplantation, contributing substantially to morbidity and non-relapse mortality. Better understanding of the immunopathophysiology of GvHD has identified a number of targets for intervention. A...

journal_title：Seminars in oncology

authors： Bruner RJ,Farag SS

更新日期：2003-08-01 00:00:00

abstract：:Navelbine (NVB) or 5' nor-anhydro-vinblastine was shown to present a broader antitumor activity and to induce fewer side effects than vinblastine (VBL) or vincristine (VCR). The possible mechanisms of these differences were analyzed with in vitro methods. At substoichiometric concentrations, the three drugs inhibit mi...

journal_title：Seminars in oncology

authors： Fellous A,Ohayon R,Vacassin T,Binet S,Lataste H,Krikorian A,Couzinier JP,Meininger V

更新日期：1989-04-01 00:00:00

abstract：:Organ function preservation in patients with head and neck cancer can be achieved by intensity-modulated radiation therapy (IMRT). Much of the work on the physics of IMRT has been done for currently available IMRT systems. However, clinical data remain scarce. Before IMRT is accepted as a standard of care, more compre...

journal_title：Seminars in oncology

authors： Chao KS,Ozyigit G,Thorsdad WL

更新日期：2003-12-01 00:00:00

abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

journal_title：Seminars in oncology

authors： Cella D

更新日期：2004-12-01 00:00:00